Phase II/III Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax U2-V Compared to Ublituximab and Umbralisib U2 in Subjects with Chronic Lymphocytic Leukemia CLL

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03801525

Study #:
STUDY00143724

Start Date:
Aug 19, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03801525

View Complete Trial Details & Eligibility at ClinicalTrials.gov